Current concepts in the diagnosis and management of cytokine release syndrome von Lee, Daniel W., Gardner, Rebecca, Porter, David L., Louis, Chrystal U., Ahmed, Nabil, Jensen, Michael, Grupp, Stephan A., Mackall, Crystal L.

Volltext

Chimeric Antigen Receptor Therapy for Cancer von Barrett, David M, Singh, Nathan, Porter, David L, Grupp, Stephan A, June, Carl H

Volltext

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia von Mueller, Karen Thudium, Maude, Shannon L., Porter, David L., Frey, Noelle, Wood, Patricia, Han, Xia, Waldron, Edward, Chakraborty, Abhijit, Awasthi, Rakesh, Levine, Bruce L., Melenhorst, J. Joseph, Grupp, Stephan A., June, Carl H., Lacey, Simon F.

Volltext

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes von Scott, Bart L, Pasquini, Marcelo C, Logan, Brent R, Wu, Juan, Devine, Steven M, Porter, David L, Maziarz, Richard T, Warlick, Erica D, Fernandez, Hugo F, Alyea, Edwin P, Hamadani, Mehdi, Bashey, Asad, Giralt, Sergio, Geller, Nancy L, Leifer, Eric, Le-Rademacher, Jennifer, Mendizabal, Adam M, Horowitz, Mary M, Deeg, H Joachim, Horwitz, Mitchell E

Volltext

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies von Ruella, Marco, Barrett, David M, Kenderian, Saad S, Shestova, Olga, Hofmann, Ted J, Perazzelli, Jessica, Klichinsky, Michael, Aikawa, Vania, Nazimuddin, Farzana, Kozlowski, Miroslaw, Scholler, John, Lacey, Simon F, Melenhorst, Jan J, Morrissette, Jennifer J D, Christian, David A, Hunter, Christopher A, Kalos, Michael, Porter, David L, June, Carl H, Grupp, Stephan A, Gill, Saar

Volltext

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance von Boyiadzis, Michael M, Dhodapkar, Madhav V, Brentjens, Renier J, Kochenderfer, James N, Neelapu, Sattva S, Maus, Marcela V, Porter, David L, Maloney, David G, Grupp, Stephan A, Mackall, Crystal L, June, Carl H, Bishop, Michael R

Volltext

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease von Reshef, Ran, Luger, Selina M, Hexner, Elizabeth O, Loren, Alison W, Frey, Noelle V, Nasta, Sunita D, Goldstein, Steven C, Stadtmauer, Edward A, Smith, Jacqueline, Bailey, Sarah, Mick, Rosemarie, Heitjan, Daniel F, Emerson, Stephen G, Hoxie, James A, Vonderheide, Robert H, Porter, David L

Volltext

Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BM... von Scott, Bart L., Pasquini, Marcelo C., Fei, Mingwei, Fraser, Raphael, Wu, Juan, Devine, Steve M., Porter, David L., Maziarz, Richard T., Warlick, Erica, Fernandez, Hugo F., Soiffer, Robert J., Alyea, Edwin, Hamadani, Mehdi, Bashey, Asad, Giralt, Sergio, Geller, Nancy L., Leifer, Eric, Hourigan, Christopher S., Gui, Gege, Mendizabal, Adam, Horowitz, Mary M., Deeg, H. Joachim, Horwitz, Mitchell E.

Volltext

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis von Moy, Ryan H., Huffman, Austin P., Richman, Lee P., Crisalli, Lisa, Wang, Ximi K., Hoxie, James A., Mick, Rosemarie, Emerson, Stephen G., Zhang, Yi, Vonderheide, Robert H., Porter, David L., Reshef, Ran

Volltext

Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies von Freyer, Craig W., Porter, David L.

Volltext

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia von Maude, Shannon L., Teachey, David T., Porter, David L., Grupp, Stephan A.

Volltext

Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia von Connor, Matthew P, Prathapa, Neeharika, Frey, Noelle V, Gill, Saar I, Hexner, Elizabeth O, Bruno, Ximena Jordan, Lai, Catherine E, Loren, Alison W, Luger, Selina M, Matthews, Andrew H, McCurdy, Shannon R, Perl, Alexander E, Porter, David L, Zeringue, Arlene, Oved, Joseph H, Olson, Timothy S, Pratz, Keith W, Babushok, Daria V

Volltext

Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract von Ganetsky, Alex, Frey, Noelle V., Hexner, Elizabeth O., Loren, Alison W., Gill, Saar I., Luger, Selina M., Mangan, James K., Martin, Mary Ellen, Babushok, Daria V., Drobyski, William R., Smith, Jacqueline, Timlin, Colleen, Freyer, Craig W., Stadtmauer, Edward A., Porter, David L.

Volltext

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas von Riedell, Peter A., Hwang, Wei-Ting, Nastoupil, Loretta J., Pennisi, Martina, McGuirk, Joseph P., Maziarz, Richard T., Bachanova, Veronika, Oluwole, Olalekan O., Brower, Jamie, Flores, Oscar A., Ahmed, Nausheen, Schachter, Levanto, Bharucha, Kharmen, Dholaria, Bhagirathbhai R., Schuster, Stephen J., Perales, Miguel-Angel, Bishop, Michael R., Porter, David L.

Volltext

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia von Matthews, Andrew H., Perl, Alexander E., Luger, Selina M., Loren, Alison W., Gill, Saar I., Porter, David L., Babushok, Daria V., Maillard, Ivan P., Carroll, Martin P., Frey, Noelle V., Hexner, Elizabeth O., Martin, Mary Ellen, McCurdy, Shannon R., Stadtmauer, Edward A., Paralkar, Vikram R., Bruno, Ximena Jordan, Hwang, Wei-Ting, Margolis, David, Pratz, Keith W.

Volltext

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia von Porter, David L, Levine, Bruce L, Kalos, Michael, Bagg, Adam, June, Carl H

Volltext

Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia von Frey, Noelle V, Porter, David L

Volltext

Chimeric antigen receptor T cell therapy: 25 years in the making von Gill, Saar, Maus, Marcela V, Porter, David L

Volltext

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells von Melenhorst, J. Joseph, Chen, Gregory M., Wang, Meng, Porter, David L., Chen, Changya, Collins, McKensie A., Gao, Peng, Bandyopadhyay, Shovik, Sun, Hongxing, Zhao, Ziran, Lundh, Stefan, Pruteanu-Malinici, Iulian, Nobles, Christopher L., Maji, Sayantan, Frey, Noelle V., Gill, Saar I., Loren, Alison W., Tian, Lifeng, Kulikovskaya, Irina, Gupta, Minnal, Ambrose, David E., Davis, Megan M., Fraietta, Joseph A., Brogdon, Jennifer L., Young, Regina M., Chew, Anne, Levine, Bruce L., Siegel, Donald L., Alanio, Cécile, Wherry, E. John, Bushman, Frederic D., Lacey, Simon F., Tan, Kai, June, Carl H.

Volltext

Antibody-modified T cells: CARs take the front seat for hematologic malignancies von Maus, Marcela V., Grupp, Stephan A., Porter, David L., June, Carl H.

Volltext